Looking for Sentiment Analysis? Discover the most popular stocks on Reddit by using our Sentiment Tracker
Market Cap 101.99M P/E - EPS this Y 29.80% Ern Qtrly Grth -
Income -108.3M Forward P/E -1.16 EPS next Y 14.60% 50D Avg Chg 4.00%
Sales 73.48M PEG 0.06 EPS past 5Y - 200D Avg Chg -11.00%
Dividend N/A Price/Book 0.53 EPS next 5Y -13.70% 52W High Chg -61.00%
Recommedations 2.00 Quick Ratio 2.79 Shares Outstanding 51.21M 52W Low Chg 26.00%
Insider Own 0.82% ROA -23.25% Shares Float 42.06M Beta 1.95
Inst Own 56.93% ROE -62.31% Shares Shorted/Prior 1.08M/0.91M Price 2.18
Gross Margin 24.78% Profit Margin -147.38% Avg. Volume 239,790 Target Price 4.75
Oper. Margin -101.31% Earnings Date May 8 Volume 213,449 Change -3.11%
About Personalis, Inc.

Personalis, Inc. develops and markets advanced cancer genomic tests and analytics primarily in the United States, Europe, and the Asia-Pacific. Its tests and analytics are used by pharmaceutical companies for translational research, biomarker discovery, and development of personalized cancer therapies, as well as advanced tests are used by physicians to detect cancer recurrence, monitor cancer evolution, and uncover insights for therapy selection. The company offers NeXT Personal, a tumor-informed liquid biopsy test for detection of minimal residual disease (MRD) and recurrence in cancer; and ImmunoID NeXT, a tissue-based test that combines whole exome (DNA) and whole transcriptome (RNA) sequencing data with advanced analytics to provide a multi-dimensional view of the tumor and the tumor microenvironment from a single sample. It also provides NeXT Personal Dx, a tumor-informed liquid biopsy test for detection of MRD and recurrence in cancer; and NeXT Dx, a comprehensive tumor profiling test that unlocks the entire exome (DNA) and transcriptome (RNA) with matched tumor-normal analysis. In addition, the company performs whole exome sequencing (WES) of cancer tissue and matched blood samples for diagnostic companies as an input to their products; and whole genome sequencing (WGS) on human samples for research projects, such as population sequencing initiatives, as well as offers sequencing and data analysis services to support population sequencing initiatives. Its customers include pharmaceutical companies, biopharmaceutical companies, diagnostics companies, universities, non-profits, government entities, and patients. The company was incorporated in 2011 and is headquartered in Fremont, California.

Personalis, Inc. News
04/24/24 Personalis to Announce First Quarter 2024 Financial Results
03/28/24 Personalis to Present at the 23rd Annual Needham Virtual Healthcare Conference
03/28/24 Data Showcasing NeXT Personal MRD Test to be Presented at the 2024 American Association for Cancer Research (AACR) Annual Meeting
03/26/24 Personalis Announces Publication Validating NeXT Personal® Test for Ultra-sensitive MRD Detection and Cancer Treatment Response Monitoring
03/19/24 Personalis Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
02/29/24 Personalis, Inc. (NASDAQ:PSNL) Q4 2023 Earnings Call Transcript
02/28/24 Personalis Reports Fourth Quarter and Full Year 2023 Financial Results
02/14/24 Personalis to Announce Fourth Quarter and Full Year 2023 Financial Results
01/31/24 Personalis to Participate at Upcoming Investor Conferences
01/30/24 Personalis and ClearNote Health Announce Partnership to Advance Epigenomic Technology
01/16/24 Personalis Announces Medicare Coverage for NeXT Dx(R) Comprehensive Genomic Tumor Profiling Assay
01/05/24 Personalis Reports Preliminary Fourth Quarter and Full Year 2023 Revenue and Cash Balance
12/18/23 Even With A 37% Surge, Cautious Investors Are Not Rewarding Personalis, Inc.'s (NASDAQ:PSNL) Performance Completely
12/04/23 Personalis Extends Cash Position Into 2026, Provides Update on Key Initiatives
11/28/23 Personalis and Tempus Enter into a Strategic Collaboration to Advance Cancer Testing
11/08/23 Personalis, Inc. (NASDAQ:PSNL) Q3 2023 Earnings Call Transcript
11/07/23 Personalis Reports Third Quarter 2023 Financial Results
10/26/23 Personalis Launches NeXT Personal® Dx for Early Access Clinical Use in Residual Disease and Recurrence Detection in Cancer
10/24/23 Personalis to Announce Third Quarter 2023 Financial Results
10/21/23 Analysis from TRACERx Study Reveals More Sensitive and Earlier ctDNA Detection in Lung Cancer Patients by Personalis' MRD Technology
PSNL Chatroom

User Image stockswinger14 Posted - 4 hours ago

$PSNL I have no clue how many shares cathie has bought but ark must be decently bullish here for a long swing. I’m good with $2+ easy money

User Image Stock_Titan Posted - 11 hours ago

$PSNL Personalis to Announce First Quarter 2024 Financial Results https://www.stocktitan.net/news/PSNL/personalis-to-announce-first-quarter-2024-financial-phwpz4wuknvz.html

User Image moneyMunkey Posted - 15 hours ago

$PSNL ASCO 24 abstract titles are out… looks like they are listed on 5 plus the moderna cancer vaccine ones. might be some more with some other companys they are working with to not sure.

User Image BeeDecay Posted - 20 hours ago

@ExNoose The shitty thing is that the full ARK involvement works strongly against the stocks in the fund. She indeed buys some $PSNL . This assures her belief in the company. But at the same time ARK sees an unseen exodus. 2.2B already this year. Same as full 2023. Because of the working principle of ETF this means she actually SELLS all holdings at a ratio of their weight in the fund. These are not reported for logical reasons since they do not alter the weights of individual companies. These exits outweigh the nibbling of some shares. Added to that, there is an INFLOW in the ARK short ETFs. These inflows in fact means… selling shares as well (short positions). These betting against ARK are becoming more of a problem seen their increasing weight. I believe in the company but hold my breath for the stock.

User Image stockswinger14 Posted - 1 day ago

$PSNL starter swing position taken , looking for 15-20%

User Image RocketThief Posted - 1 day ago

$PSNL nice to finally see some spunk from this abomination

User Image ExNoose Posted - 1 day ago

$PSNL Nice hold so far. We just need increase in weekly volume and a break of the TL and the 50EMA.

User Image Albano_Corleone Posted - 2 days ago

$PSNL hasnt moved after bell?

User Image arribaStocktrading Posted - 2 days ago

$PSNL One of my stocks is being bought out today (MTTR). What's notable about that is that the stock was trading @1.75 at the time of announcement and the buyout price is $5.50/share. I present this as evidence that the shit valuations the market is pinning on many stocks does not reflect their true value. Why did the market makers keep driving that stock's price down? Because they can. I hope we get a buyout here for $5.50 or more too. $10/share and I'm retiring!

User Image ExNoose Posted - 5 days ago

$PSNL PSNL and bonds its kinda the same thing. Both safe havens lol

User Image DC729 Posted - 6 days ago

@financials_please @sogenerous how are $PACB and $PSNL comparable? One is a squencing infrastructure vs cancer tests. $PSNL just needs to get final Medicare reimbursement for a few indications which is the goal this year.

User Image sogenerous Posted - 6 days ago

As all the other genomics companies go bankrupt like $NVTA $PSNL $PACB - hopefully $ILMN will be last man standing and a resurgent eventually

User Image ExNoose Posted - 1 week ago

$PSNL Check out this interview with Dr. Christoffer Gebhardt (@DocChristOffer) where he discusses findings presented at #AACR24 from a retrospective study in #melanoma patients which utilized NeXT Personal. #ctDNA dynamics detected with NeXT Personal were predictive of patient response and outcomes in melanoma patients receiving immunotherapy. Moreover, a third of ctDNA detections were in the ultra-sensitive range (below 100 PPM) highlighting the need for an ultra-sensitive approach. https://crowd-funding.givetaxfree.org/ultra-sensitive-ctdna-monitoring-predicts-ici-response-in-melanoma-video/?utm_source=dlvr.it&utm_medium=twitter

User Image Londonlight Posted - 1 week ago

$PSNL crypto down 5% euro stocks worst day for 9 months, none of this bodes well. Middle East unease driving

User Image Wax_Bean_futures Posted - 1 week ago

$PSNL Hope we can maintain $1, or I will start dumping shares, as I did last time 😕

User Image themarker Posted - 1 week ago

Cathie Wood and Ark Invest's trade activity from 2024/04/16 $BLDE $PSNL

User Image ExNoose Posted - 1 week ago

$PSNL Cathy been nibbling PSNL everyday. I think she likes were the cancer vaccine is going , thats why she bought MRNA as well. Lets see.

User Image MLinv Posted - 1 week ago

$PSNL Scaled back in previous secured gains and some more at 1.23 and averaged down from 1.48 to 1.39 avg $ARKG

User Image ExNoose Posted - 1 week ago

$PSNL gap almost filled at $23.85 for $ARKG and 10Y at the top of the channel. Good chance we find a bottom today. $NTLA $CRSP

User Image themarker Posted - 1 week ago

Cathie Wood and Ark Invest's trade activity from 2024/04/15 $BLDE $PSNL

User Image NYG4ever Posted - 1 week ago

$PSNL def the most frustrating stock in my portfolio

User Image ExNoose Posted - 1 week ago

$CRSP $PSNL $NTLA 10Y almost topped, we are near bottom imo

User Image BeeDecay Posted - 1 week ago

@Londonlight indeed. These ARE relevant. $PSNL will need to raise money. $PSNL needs to comply with the minimum bid requirement. A bad macro economic situation makes both aspects challenging. Especially when no major news is imminent.

User Image docone Posted - 1 week ago

$PSNL pretty sure no debt which is very nice compared to most stocks in this group

User Image themarker Posted - 1 week ago

Cathie Wood and Ark Invest's trade activity from 2024/04/12 $ARCT $BLDE $PSNL

User Image Londonlight Posted - 1 week ago

$PSNL back to a $1 again at this rate, depressing

User Image BeeDecay Posted - 1 week ago

$PSNL they were very active at AACR but nobody seems to care about the progress they make. Bitter pill to swallow.

User Image ExNoose Posted - 1 week ago

$PSNL volume decline since 2 ER ago, lets see what happens

User Image arribaStocktrading Posted - 1 week ago

$PSNL Not to worry... Once NVDA wakes up, the market will look like a glorious weekend in the Hamptons. ( Seinfeld reference for those who catch it) .... at least to the untrained eye and all the stupid idiots who write for WSJ, Barrons, Marketwatch and the like. (Remind me not to renew my subscriptions to any of these) This is a heartbreak economy for most but you have lies, damn lies and statistics to do the heavy lifting of saying otherwise.

User Image themarker Posted - 1 week ago

Cathie Wood and Ark Invest's trade activity from 2024/04/11 $ARCT $BLDE $PLTR $PSNL

Analyst Ratings
Needham Buy Apr 11, 24
Needham Buy Feb 29, 24
Needham Buy Jan 5, 24
Needham Buy Nov 8, 23
HC Wainwright & Co. Buy Aug 9, 23
Needham Buy Aug 9, 23
HC Wainwright & Co. Buy May 4, 23
Needham Buy May 4, 23
Morgan Stanley Equal-Weight Feb 27, 23
Insider Trades Relationship Date Transactions Cost($) #Shares Value($) #Share Own SEC Form 4
Chen Richard Chief Medical Office.. Chief Medical Officer and EVP Dec 15 Sell 1.47 4,708 6,921 129,396 12/19/23
Tachibana Aaron CFO and COO CFO and COO Dec 15 Sell 1.47 6,747 9,918 185,237 12/19/23
Moore Stephen Michael General Counsel General Counsel Dec 15 Sell 1.47 1,476 2,170 76,920 12/19/23
Moore Stephen Michael General Counsel General Counsel Nov 16 Sell 1.04 1,722 1,791 78,396 11/20/23
Tachibana Aaron CFO and COO CFO and COO Nov 16 Sell 1.04 1,344 1,398 191,984 11/20/23
Chen Richard Chief Medical Office.. Chief Medical Officer and EVP Nov 16 Sell 1.04 940 978 124,104 11/20/23
Hall Christopher M President and CEO President and CEO Nov 01 Sell 0.93 20,459 19,027 204,541 11/03/23
Chen Richard Chief Medical Office.. Chief Medical Officer and EVP May 17 Sell 1.98 971 1,923 130,346 05/19/23
Tachibana Aaron CFO and COO CFO and COO Mar 17 Sell 2.83 3,945 11,164 202,283 03/21/23
Chen Richard Chief Medical Office.. Chief Medical Officer and EVP Mar 17 Sell 2.83 1,314 3,719 131,317 03/21/23
Tachibana Aaron Chief Financial Offi.. Chief Financial Officer Jan 31 Sell 2.20 767 1,687 206,228 02/02/23
Tachibana Aaron Chief Financial Offi.. Chief Financial Officer Dec 02 Sell 2.60 4,360 11,336 218,015 12/06/22
Chen Richard Chief Medical Office.. Chief Medical Officer Dec 02 Sell 2.60 440 1,144 142,120 12/06/22
Moore Stephen Michael General Counsel General Counsel Nov 16 Sell 2.71 2,045 5,542 90,440 11/18/22
Tachibana Aaron Chief Financial Offi.. Chief Financial Officer Nov 16 Sell 2.71 1,294 3,507 222,375 11/18/22
Chen Richard Chief Medical Office.. Chief Medical Officer Sep 20 Sell 3.48 1,581 5,502 143,855 09/22/22
Tachibana Aaron Chief Financial Offi.. Chief Financial Officer Sep 20 Sell 3.48 3,474 12,090 223,669 09/22/22
Chen Richard Chief Medical Office.. Chief Medical Officer Sep 02 Sell 3.33 420 1,399 145,436 09/08/22
Chen Richard Chief Medical Office.. Chief Medical Officer Jul 28 Sell 3.91 632 2,471 145,856 08/01/22
Tachibana Aaron Chief Financial Offi.. Chief Financial Officer Jul 28 Sell 3.91 632 2,471 231,311 08/01/22
Chen Richard Chief Medical Office.. Chief Medical Officer Jun 17 Sell 3.29 1,565 5,149 146,488 06/21/22
Tachibana Aaron Chief Financial Offi.. Chief Financial Officer Jun 17 Sell 3.29 3,440 11,318 231,943 06/21/22
Moore Stephen Michael General Counsel General Counsel Jun 15 Sell 3.24 1,832 5,936 73,885 06/17/22
Tachibana Aaron Chief Financial Offi.. Chief Financial Officer Jun 15 Sell 3.24 6,818 22,090 235,383 06/17/22
Tachibana Aaron Chief Financial Offi.. Chief Financial Officer Jun 02 Sell 3.59 4,187 15,031 242,201 06/06/22
Chen Richard Chief Medical Office.. Chief Medical Officer Jun 02 Sell 3.59 421 1,511 154,871 06/06/22
Tachibana Aaron Chief Financial Offi.. Chief Financial Officer May 16 Sell 4.86 1,286 6,250 246,388 05/18/22
West John Stephen President and CEO President and CEO May 16 Sell 4.86 2,408 11,703 382,444 05/18/22
Moore Stephen Michael General Counsel General Counsel May 16 Sell 4.86 664 3,227 75,717 05/18/22
Chen Richard Chief Medical Office.. Chief Medical Officer May 16 Sell 4.86 1,286 6,250 155,830 05/18/22
Moore Stephen Michael General Counsel General Counsel May 02 Sell 5.53 5,733 31,703 76,381 05/04/22
West John Stephen President and CEO President and CEO Apr 20 Option 1.84 45,061 82,912 384,852 04/22/22
West John Stephen President and CEO President and CEO Apr 13 Option 1.84 64,430 118,551 404,221 04/15/22
Lightspeed Venture Partners Se... Other Other Mar 02 Buy 10.06 314,750 3,166,385 4,750 03/04/22
Chen Richard Chief Medical Office.. Chief Medical Officer Mar 02 Sell 10.18 471 4,795 157,334 03/04/22
Tachibana Aaron Chief Financial Offi.. Chief Financial Officer Mar 02 Sell 10.18 4,511 45,922 251,441 03/04/22
Chen Richard Chief Medical Office.. Chief Medical Officer Jan 28 Sell 9.93 705 7,001 157,805 02/01/22
Tachibana Aaron Chief Financial Offi.. Chief Financial Officer Jan 28 Sell 9.93 705 7,001 255,952 02/01/22
West John Stephen President and CEO President and CEO Jan 18 Sell 11.37 99,987 1,136,852 285,457 01/19/22
West John Stephen President and CEO President and CEO Jul 12 Sell 22.54 110,000 2,479,400 635,520 07/12/21
West John Stephen President and CEO President and CEO Jun 10 Sell 22.66 110,000 2,492,600 560,520 06/10/21
Chen Richard Chief Scientific Off.. Chief Scientific Officer Dec 03 Option 0.44 40,000 17,600 152,750 12/03/20
Chen Richard Chief Scientific Off.. Chief Scientific Officer Dec 03 Sell 27.88 40,293 1,123,369 112,457 12/03/20
Abingworth LLP 10% Owner 10% Owner Oct 14 Sell 28.76 202,360 5,819,874 4,260,092 10/14/20
Chen Richard Chief Scientific Off.. Chief Scientific Officer Oct 05 Option 0.44 37,452 16,479 152,750 10/05/20
Chen Richard Chief Scientific Off.. Chief Scientific Officer Oct 05 Sell 21.97 40,000 878,800 112,750 10/05/20